EKF Diagnostics Investor Announcements

EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.

1st Apr 2022

EKF announces that it has purchased a total of 750,000 of its ordinary shares at a price of 44.1667 pence per share

31st Mar 2022

EKF has purchased a total of 900,000 of its ordinary shares at a price of 44.6667 pence per share.

29th Mar 2022

EKF has purchased a total of 1,300,000 of its ordinary shares at an average price of 45.0962 pence per share

29th Mar 2022

EKF announces that it intends to conduct on-market purchases under a share buyback programme

29th Mar 2022

Final results for the year ended 31 December 2021. 

Additional enzyme production capacity to accelerate EKF’s organic growth strategy

EKF notes the announcements released by Verici Dx plc on 4 March 2022 relating to the successful Placing for Verici Dx, a developer of advanced clinical diagnostics for organ transplant.

EKF will announce its preliminary results for the year ended 31 December 2021 on Tuesday 29 March 2022.

EKF announces the appointment of Jenny Winter as Non-executive Director (“NED”), effective on 1 February 2022. At the same time Carl Contadini, Non-executive Director, will stand down from the Board.

25th Jan 2022

EKF confirms that continued strong trading will result in its performance for the financial year ended 31 December 2021, including adjusted EBITDA, being ahead of already upgraded market expectations.



  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011

Mount Sinai investments related

RNS announcements